Laboratory of Histology, Department of Health Sciences, Università del Piemonte Orientale "A. Avogadro", Novara, Italy.
Can J Physiol Pharmacol. 2012 Mar;90(3):317-25. doi: 10.1139/y11-125. Epub 2012 Feb 24.
Direct reprogramming of somatic cells into pluripotent cells is an emerging technology for creating patient-specific cells, and potentially opens new scenarios in medical and pharmacological fields. From the discovery of Shinya Yamanaka, who first obtained pluripotent cells from fibroblasts by retrovirus-derived ectopic expression of defined embryonic transcription factors, new methods have been developed to generate safe induced pluripotent stem (iPS) cells without genomic manipulations. This review will focus on the recent advances in iPS technology and their application in pharmacology and medicine.
体细胞直接重编程为多能细胞是一种新兴的技术，可用于创建患者特异性细胞，并可能在医学和药理学领域开辟新的应用场景。自 Shinya Yamanaka 发现通过逆转录病毒衍生的外源性表达定义的胚胎转录因子可从成纤维细胞中获得多能细胞以来，已经开发了新的方法来生成安全的无基因组操作的诱导多能干细胞（iPS）细胞。本综述将重点介绍 iPS 技术的最新进展及其在药理学和医学中的应用。
